PsyBio Therapeutics Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Evan Mike Levine
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4400 West Sample Road Coconut Creek FL United States of America 33073
- IPO Date
- Apr 23, 2021
- CIK
- 0001833371
- Website
- psybiolife.com
- Similar Companies
- Business
- PsyBio Therapeutics Corp. (TSXV: PSYB; OTCQB: PSYBF) is a biotechnology company focused on the discovery, design, and development of novel psycho-targeted therapeutics derived from psychedelic-inspired regulated medicines to treat mental health challenges and neurological disorders. The company develops biosynthetic tryptamines, including its lead candidate PsyBio-11142, along with a portfolio of over 80 proprietary molecules such as precursors and analogs of naturally occurring psychoactive tryptamines from hallucinogenic mushrooms, phenethylamines, and combinations thereof; it employs a bio-medicinal chemistry approach utilizing synthetic biology and metabolic engineering for production. PsyBio Therapeutics maintains research and manufacturing facilities in Oxford, Ohio, and Denver, Colorado; operations span the United States and Canada; founded in 2009 and headquartered at 1624 Washington Street, Denver, Colorado. In July 2023, the company secured government approval to manufacture biosynthetic tryptamines at scale, marking it as the first biotechnology firm with such formal authorization; it continues sponsored research agreements with Miami University, amended in 2021 to extend funding through May 2023 for psilocybin production strategies and psychology department efforts; in February 2023, CEO Evan Levine received the Best Pitch Award at Kahner Global’s Cannabis & Psychedelics Investment Summit.
PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA
PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences
PsyBio Therapeutics shares updates on intellectual property and clinical development milestones
PsyBio Therapeutics is developing psychoactive compounds which could be a mental health game changer
PsyBio Therapeutics announces expansion of its intellectual property portfolio by filing six additional patent applications
PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
PsyBio Therapeutics successfully demonstrates commercial-scale manufacturing feasibility
PsyBio Therapeutics submits its first pre-IND application meeting request to FDA
PsyBio Therapeutics inducted into AdvisorShares Psychedelics ETF